Hiroki Takanari1, Vincent J A Bourgonje2, Magda S C Fontes2, Antonia J A Raaijmakers2, Helen Driessen2, John A Jansen2, Roel van der Nagel2, Bart Kok2, Leonie van Stuijvenberg2, Mohamed Boulaksil3, Yoshio Takemoto4, Masatoshi Yamazaki4, Yukiomi Tsuji4, Haruo Honjo4, Kaichiro Kamiya4, Itsuo Kodama5, Mark E Anderson6, Marcel A G van der Heyden2, Harold V M van Rijen2, Toon A B van Veen7, Marc A Vos2. 1. Department of Medical Physiology, Division of Heart & Lungs, University Medical Center Utrecht, Utrecht, The Netherlands Department of Cardiovascular Research, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Japan Department of Pathophysiology, Oita University School of Medicine, Yufu, Japan. 2. Department of Medical Physiology, Division of Heart & Lungs, University Medical Center Utrecht, Utrecht, The Netherlands. 3. Department of Medical Physiology, Division of Heart & Lungs, University Medical Center Utrecht, Utrecht, The Netherlands Department of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands. 4. Department of Cardiovascular Research, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Japan. 5. Nagoya University, Nagoya, Japan. 6. Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MA, USA. 7. Department of Medical Physiology, Division of Heart & Lungs, University Medical Center Utrecht, Utrecht, The Netherlands a.a.b.vanveen@umcutrecht.nl.
Abstract
AIM: In healthy hearts, ventricular gap junctions are mainly composed by connexin43 (Cx43) and localize in the intercalated disc, enabling appropriate electrical coupling. In diseased hearts, Cx43 is heterogeneously down-regulated, whereas activity of calmodulin/calcium-calmodulin protein kinase II (CaM/CaMKII) signalling increases. It is unclear if CaM/CaMKII affects Cx43 expression/localization or impulse propagation. We analysed different models to assess this. METHODS AND RESULTS: AC3-I mice with CaMKII genetically inhibited were subjected to pressure overload (16 weeks, TAC vs. sham). Optical and epicardial mapping was performed on Langendorff-perfused rabbit and AC3-I hearts, respectively. Cx43 subcellular distribution from rabbit/mouse ventricles was evaluated by immunoblot after Triton X-100-based fractionation. In mice with constitutively reduced CaMKII activity (AC3-I), conduction velocity (CV) was augmented (n = 11, P < 0.01 vs. WT); in AC3-I, CV was preserved after TAC, in contrast to a reduction seen in TAC-WT mice (-20%). Cx43 expression was preserved after TAC in AC3-I mice, though arrhythmias and fibrosis were still present. In rabbits, W7 (CaM inhibitor, 10 µM) increased CV (6-13%, n= 6, P< 0.05), while susceptibility to arrhythmias decreased. Immunoconfocal microscopy revealed enlarged Cx43 cluster sizes at intercalated discs of those hearts. Total Cx43 did not change by W7 (n= 4), whereas Triton X-100 insoluble Cx43 increased (+21%, n= 4, P< 0.01). Similar findings were obtained in AC3-I mouse hearts when compared with control, and in cultured dog cardiomyocytes. Functional implication was shown through increased intercellular coupling in cultured neonatal rat cardiomyocytes. CONCLUSION: Both acute and chronic CaM/CaMKII inhibition improves conduction characteristics and enhances localization of Cx43 in the intercalated disc. In the absence of fibrosis, this reduced the susceptibility for arrhythmias. Published on behalf of the European Society of Cardiology. All rights reserved.
AIM: In healthy hearts, ventricular gap junctions are mainly composed by connexin43 (Cx43) and localize in the intercalated disc, enabling appropriate electrical coupling. In diseased hearts, Cx43 is heterogeneously down-regulated, whereas activity of calmodulin/calcium-calmodulin protein kinase II (CaM/CaMKII) signalling increases. It is unclear if CaM/CaMKII affects Cx43 expression/localization or impulse propagation. We analysed different models to assess this. METHODS AND RESULTS: AC3-I mice with CaMKII genetically inhibited were subjected to pressure overload (16 weeks, TAC vs. sham). Optical and epicardial mapping was performed on Langendorff-perfused rabbit and AC3-I hearts, respectively. Cx43 subcellular distribution from rabbit/mouse ventricles was evaluated by immunoblot after Triton X-100-based fractionation. In mice with constitutively reduced CaMKII activity (AC3-I), conduction velocity (CV) was augmented (n = 11, P < 0.01 vs. WT); in AC3-I, CV was preserved after TAC, in contrast to a reduction seen in TAC-WT mice (-20%). Cx43 expression was preserved after TAC in AC3-I mice, though arrhythmias and fibrosis were still present. In rabbits, W7 (CaM inhibitor, 10 µM) increased CV (6-13%, n= 6, P< 0.05), while susceptibility to arrhythmias decreased. Immunoconfocal microscopy revealed enlarged Cx43 cluster sizes at intercalated discs of those hearts. Total Cx43 did not change by W7 (n= 4), whereas Triton X-100 insoluble Cx43 increased (+21%, n= 4, P< 0.01). Similar findings were obtained in AC3-I mouse hearts when compared with control, and in cultured dog cardiomyocytes. Functional implication was shown through increased intercellular coupling in cultured neonatal rat cardiomyocytes. CONCLUSION: Both acute and chronic CaM/CaMKII inhibition improves conduction characteristics and enhances localization of Cx43 in the intercalated disc. In the absence of fibrosis, this reduced the susceptibility for arrhythmias. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: John A Jansen; Maartje Noorman; Hassan Musa; Mèra Stein; Sanne de Jong; Roel van der Nagel; Thomas J Hund; Peter J Mohler; Marc A Vos; Toon A van Veen; Jacques M de Bakker; Mario Delmar; Harold V van Rijen Journal: Heart Rhythm Date: 2011-11-16 Impact factor: 6.343
Authors: Michelle S C Khoo; Jingdong Li; Madhu V Singh; Yingbo Yang; Prince Kannankeril; Yuejin Wu; Chad E Grueter; Xiaoqun Guan; Carmine V Oddis; Rong Zhang; Lisa Mendes; Gemin Ni; Ernest C Madu; Jinying Yang; Martha Bass; Rey J Gomez; Brian E Wadzinski; Eric N Olson; Roger J Colbran; Mark E Anderson Journal: Circulation Date: 2006-09-18 Impact factor: 29.690
Authors: Nicole M Ashpole; Anthony W Herren; Kenneth S Ginsburg; Joseph D Brogan; Derrick E Johnson; Theodore R Cummins; Donald M Bers; Andy Hudmon Journal: J Biol Chem Date: 2012-04-18 Impact factor: 5.157
Authors: Rob F Wiegerinck; Arie O Verkerk; Charly N Belterman; Toon A B van Veen; Antonius Baartscheer; Tobias Opthof; Ronald Wilders; Jacques M T de Bakker; Ruben Coronel Journal: Circulation Date: 2006-02-06 Impact factor: 29.690
Authors: Karl Toischer; Nico Hartmann; Stefan Wagner; Thomas H Fischer; Jonas Herting; Bernhard C Danner; Can M Sag; Thomas J Hund; Peter J Mohler; Luiz Belardinelli; Gerd Hasenfuss; Lars S Maier; Samuel Sossalla Journal: J Mol Cell Cardiol Date: 2013-04-06 Impact factor: 5.000
Authors: Alexey V Zaitsev; Natalia S Torres; Keiko M Cawley; Amira D Sabry; Junco S Warren; Mark Warren Journal: Am J Physiol Heart Circ Physiol Date: 2019-03-15 Impact factor: 4.733
Authors: Helen E Driessen; Magda S Fontes; Leonie van Stuijvenberg; Maike A Brans; Marie-Jose Goumans; Marc A Vos; Toon A van Veen Journal: J Cell Mol Med Date: 2020-06-23 Impact factor: 5.310